Press release
Actinic Keratosis Pipeline: 10+ Key Players Driving Innovation in Non-Invasive Dermatological Treatments | DelveInsight
Actinic Keratosis Pipeline
DelveInsight's "Actinic Keratosis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the actinic keratosis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging actinic keratosis drugs, the actinic keratosis pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Explore the full pipeline analysis for actinic keratosis and uncover key opportunities @ https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Actinic Keratosis Pipeline Report
• DelveInsight's actinic keratosis pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for Actinic Keratosis treatment.
• The leading actinic keratosis companies include VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, DermAct Pharmaceutical, Sol-Gel Technologies, Provectus Biopharmaceuticals, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and others are evaluating their lead assets to improve the actinic keratosis treatment landscape.
• Key actinic keratosis pipeline therapies in various stages of development include VDA-1102, NanoPac, SR T100, DFD-07, AVX001, JW-200, MDC 2040, SGT 210, and others.
• In October 2024, Biofrontera Inc. (Nasdaq: BFRI) announced FDA approval of its sNDA to expand the maximum dosage of Ameluz® from one to three tubes per treatment, enabling larger field treatment of actinic keratosis on the face and scalp with Ameluz®-PDT using BF-RhodoLED or RhodoLED XL.
• In June 2024, Biofrontera Inc. launched its FDA-approved RhodoLED XL, a red LED lamp used with Ameluz® gel (10%) for photodynamic therapy (PDT) to treat mild-to-moderate actinic keratoses on the face and scalp.
Request a sample and discover the recent breakthroughs happening in the actinic keratosis pipeline landscape @ https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Actinic Keratosis Overview
Actinic keratoses (AKs) are premalignant lesions that can progress to squamous cell carcinoma (SCC). They typically present as erythematous, scaly macules or papules, most often in middle-aged or older individuals. These lesions commonly appear on sun-exposed areas such as the face, scalp, and arms. Chronic exposure to ultraviolet (UV) radiation, particularly UVA and UVB rays, is the primary factor contributing to their development, triggering genetic mutations over time. While the risk of metastatic progression from AK to SCC is low, long-term monitoring and biopsy of suspicious lesions are essential for early detection and management.
Explore top treatments for actinic keratosis now @ https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Actinic Keratosis Treatment Analysis: Drug Profile
AVX001: Coegin Pharma
AVX001 is a small-molecule drug candidate developed by Coegin Pharma that inhibits group IVa phospholipase A2 (GIVaPLA2). It is currently in Phase I/II clinical trials for the treatment of actinic keratosis.
VDA-1102: VidacPharma
VDA-1102 is a first-in-class topical anti-neoplastic agent designed to target malignant skin cells while sparing healthy tissue selectively. Its novel mechanism modulates the VDAC/HK2 complex-critical to cancer cell metabolism and mitochondrial function-inducing apoptosis specifically in cancerous cells with minimal impact on normal skin.
Learn more about the novel and emerging actinic keratosis pipeline therapies @ https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Actinic Keratosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Actinic Keratosis Pipeline Report
• Coverage: Global
• Key Actinic Keratosis Companies: VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, DermAct Pharmaceutical, Sol-Gel Technologies, Provectus Biopharmaceuticals, Coegin Pharma, Jupiter Wellness, MedC Biopharma Corporation, and others.
• Key Actinic Keratosis Pipeline Therapies: VDA-1102, NanoPac, SR T100, DFD-07, AVX001, JW-200, MDC 2040, SGT 210, and others.
Dive deep into rich insights for drugs used for actinic keratosis treatment; visit @ https://www.delveinsight.com/sample-request/actinic-keratosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Actinic Keratosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Actinic Keratosis Pipeline Therapeutics
6. Actinic Keratosis Pipeline: Late-Stage Products (Phase III)
7. Actinic Keratosis Pipeline: Mid-Stage Products (Phase II)
8. Actinic Keratosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Actinic Keratosis Pipeline: 10+ Key Players Driving Innovation in Non-Invasive Dermatological Treatments | DelveInsight here
News-ID: 3995976 • Views: …
More Releases from DelveInsight
Peripheral Arterial Clinical Trial Analysis 2025: 22+ Emerging Therapies, Novel …
DelveInsight's "Peripheral Arterial Disease - Pipeline Insight, 2025" explores over 22+ therapies in development for peripheral arterial disease (PAD), a chronic and progressive condition caused by atherosclerotic narrowing of arteries that supply blood to the limbs. Despite lifestyle modifications, antiplatelet drugs, and revascularization procedures being the current standards, a large proportion of patients continue to face critical limb ischemia, amputation risks, and poor long-term outcomes-highlighting the need for innovation in…
Ovarian Cancer Clinical Trial Analysis 2025: 200+ Pipeline Drugs, PARP Inhibitor …
DelveInsight's "Ovarian Cancer - Pipeline Insight, 2025" reviews over 200+ therapies in development for ovarian cancer, one of the most challenging gynecologic malignancies with high relapse rates. Despite advances with PARP inhibitors and chemotherapy, many patients eventually develop resistance, underscoring the urgent unmet need in the ovarian cancer treatment market.
The pipeline is diversifying with next-generation PARP inhibitors, DNA damage response (DDR) modulators, and targeted therapies such as anti-angiogenic agents and…
HER2-Positive Breast Cancer Pipeline Insight 2025: 55+ Pipeline Drugs, Targeted …
DelveInsight's "HER2-Positive Breast Cancer - Pipeline Insight, 2025" highlights over 55+ therapies in development for HER2-positive breast cancer, one of the most aggressive breast cancer subtypes. While current standards such as trastuzumab, pertuzumab, and T-DXd (trastuzumab deruxtecan) have significantly improved survival, resistance and relapse remain major challenges, sustaining unmet needs in the HER2-positive breast cancer treatment market.
The pipeline is rapidly expanding with next-generation HER2-directed therapies, including novel antibody-drug conjugates (ADCs),…
Focal Segmental Glomerulosclerosis Pipeline Insight 2025: 18+ Emerging Therapies …
DelveInsight's "Focal Segmental Glomerulosclerosis - Pipeline Insight, 2025" reviews more than 18+ therapies in development for focal segmental glomerulosclerosis (FSGS), a rare and severe form of chronic kidney disease often leading to end-stage renal failure. Current treatment strategies, including corticosteroids, calcineurin inhibitors, and supportive therapies, provide limited efficacy, leaving a high unmet need in the FSGS treatment market.
The FSGS pipeline is broadening with novel mechanisms of action, including endothelin receptor…
More Releases for Actinic
Actinic Keratosis Market Emerging Trends and Growth Prospects 2034
Introduction
Actinic keratosis (AK), also known as solar keratosis, is one of the most common precancerous skin conditions caused by long-term ultraviolet (UV) radiation exposure. It primarily affects older adults with fair skin and is considered a precursor to squamous cell carcinoma, making early detection and treatment critical. With rising awareness of skin cancer prevention, growing dermatology consultations, and expanding therapeutic innovations, the global actinic keratosis market is experiencing significant growth.
Over…
Global Actinic Keratosis Market Report Forecast to 2027
A rough, scaly area on the skin called an actinic keratosis Market develops after years of sun exposure. It commonly appears on the cheeks, lips, ears, forearms, scalp, neck, and backs of the hands. An actinic keratosis, also known as a sun keratosis, develops slowly and generally appears in persons over the age of 40. By limiting your sun exposure and protecting your skin from ultraviolet (UV) radiation, you…
Actinic Keratosis Market Insight, Epidemiology and Market Forecast -2026
The report studies the global Actinic Keratosis Market with many aspects of the industry like the market size, market status, market trends, and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. The report offers valuable insight into the Actinic Keratosis Market progress and approaches related to the market with an analysis of each region. The report goes on to…
Actinic Keratosis Treatment Market To Increase at Steady Growth Rate
Actinic keratosis (AK) is a form of skin cancer and it is also known as solar keratosis. This indication tends to affect the sun-exposed parts of the skin such as face, bald scalp, lips, and the back of the hands among others. As a result of the exposure, the skin tends to become rough, uneven and display a warty look. Approximately, 10% of the exposed areas tend to develop squamous…
United States Actinic Keratosis Treatment Market Report 2016
MarketResearchReports.biz has recently announced the addition of a market study “ United States Actinic Keratosis Treatment Market Report 2016 ”, is a comparative analysis of the global market.
Notes:
Sales, means the sales volume of Actinic Keratosis Treatment
Revenue, means the sales value of Actinic Keratosis Treatment
This report studies sales (consumption) of Actinic Keratosis Treatment in United States market, focuses on the top players, with sales, price, revenue and market…
Actinic Launches Ecommerce Fraud Checking Service with The 3rd Man
West Byfleet, Surrey – 3 June 2009 – With research showing consumers increasingly worried about card security when shopping online, Actinic (www.actinic.co.uk), the UK expert in ecommerce for small and medium businesses, has responded to the challenge with a major enhancement to its Actinic Payments service for combating card-not-present (CNP) fraud. Actinic Payments’ merchants now have seamless access to the anti-fraud, card verification service from The 3rd Man for no…
